Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06120205` - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening	N/A
Recruiting	`NCT06015854` - Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II	Phase 2
Recruiting	`NCT05587738` - Human Papillomavirus in Young People Epidemiological Research 4
Recruiting	`NCT05587725` - Human Papillomavirus in Young People Epidemiological Research 3

See also

Status

Clinical Trial

Phase

Enrolling by invitation

NCT06120205 - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

N/A

Recruiting

NCT06015854 - Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II

Phase 2

Recruiting

NCT05587738 - Human Papillomavirus in Young People Epidemiological Research 4

Recruiting

NCT05587725 - Human Papillomavirus in Young People Epidemiological Research 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00365378
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	September 1999
Completion date	July 2009

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms